There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Agios Pharma (AGIO – Research Report) and Flexion Therapeutics (FLXN – Research Report) with bullish sentiments.
Agios Pharma (AGIO)
In a report released today, Chad Messer from Needham maintained a Buy rating on Agios Pharma, with a price target of $69.00. The company’s shares closed last Wednesday at $47.11.
According to TipRanks.com, Messer is a 5-star analyst with an average return of 12.6% and a 50.5% success rate. Messer covers the Healthcare sector, focusing on stocks such as Phasebio Pharmaceuticals, Aeglea Biotherapeutics, and Ionis Pharmaceuticals.
Agios Pharma has an analyst consensus of Strong Buy, with a price target consensus of $63.75.
Flexion Therapeutics (FLXN)
Needham analyst Serge Belanger maintained a Buy rating on Flexion Therapeutics today and set a price target of $20.00. The company’s shares closed last Wednesday at $11.85.
According to TipRanks.com, Belanger is a 4-star analyst with an average return of 6.4% and a 53.5% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Amphastar Pharmaceuticals, KalVista Pharmaceuticals, and Collegium Pharmaceutical.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Flexion Therapeutics with a $23.00 average price target, representing an 88.5% upside. In a report issued on January 11, Raymond James also maintained a Buy rating on the stock with a $18.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.